Kenvue Inc.

KVUE Consumer Defensive Household & Personal Products NYSE

Back to Search

$17.69

+$0.08 (+0.43%)

Open: $17.56 | High: $17.71 | Low: $17.53 | Prev Close: Prev Close: $17.61

Market Cap: $33.90B

Volume: 3.0M | Avg: 36.0M

Last updated: April 20, 2026 at 04:02 PM
Featured In

This stock appears in the following dashboards:

Options Activity
Featured
Unusual Options
Featured
Options Screener
Featured
Options Activity for KVUE
Options Screener Data
Type Strike Expiration Premium Premium Yield Call Vol Put Vol P/C Ratio Rating
N/A $N/A N/A $N/A N/A% N/A N/A N/A N/A/10
View Full Options Screener
Puts/Calls Activity
Type Strike Expiration Premium Volume ROI % Breakeven Delta
N/A $N/A N/A $N/A N/A N/A% $N/A N/A
View Full Options Activity
Investment Rating
B+

Neutral

Overall Score: 60/100

Rating Breakdown:
DCF Score 5/5
100%
Strong Buy
ROE Score 4/5
80%
Buy
ROA Score 5/5
100%
Strong Buy
D/E Score 1/5
20%
Strong Sell
P/E Score 2/5
40%
Sell
P/B Score 2/5
40%
Sell
Add to Watchlist Add to Portfolio
Stock Score Analysis
E

Stock Score: 507

Comprehensive Quality Assessment

Component Breakdown:
Efficiency 45
Financial Health 45
Growth 0
Market Sentiment 10
Risk 40
Lower is better
Valuation 27
Momentum 40
View Full Stock Score Dashboard
Valuation Metrics
Valuation Ratios
P/E Ratio 23.27
P/B Ratio 3.15
P/S Ratio 2.24
EPS $0.76
Beta 0.57
Shares Outstanding 1.92B
Price Range & Moving Averages
52-Week High $25.17
52-Week Low $14.02
SMA 50 $17.93
SMA 200 $18.13
Dividend Information
Dividend Yield 4.68%
Annual Dividend $0.83
Earnings
Next Earnings May 07, 2026 12:30 PM ET
Financial Ratios
Margins
Gross Margin 58.1%
Operating Margin 17.9%
Net Margin 9.7%
Returns
ROE 13.9%
ROA 5.4%
Liquidity & Leverage
Debt/Equity 0.79
Current Ratio 0.96
Quick Ratio 0.68
Balance Sheet
Total Assets $27.08B
Total Liabilities $16.31B
Total Equity $10.77B
Cash $1.06B
Total Debt $8.52B
Net Debt $7.46B
Income Statement
Revenue $15.12B
Gross Profit $8.79B
Operating Income $2.70B
Net Income $1.47B
EBITDA $2.94B
Revenue/Share $7.89
Cash Flow
Operating CF $2.20B
CapEx $475.00M
Free Cash Flow $1.72B
Book Value/Share $5.62
Tangible Book/Share $-3.88
Equity/Share $5.62
Technical Indicators
RSI (14) 53.62 Neutral
MACD
-0.16 Signal: -0.19
Volatility 17.81%
Trading Signal Bullish
Performance & Returns
Total Returns
1 Year -16.54%
Risk-Adjusted Returns
Sharpe Ratio -0.62 Poor
Volatility (Ann.) 34.4% Moderate
vs S&P 500 (SPY)
KVUE (1Y) -16.54%
S&P 500 (1Y) +14.41%
Alpha (Excess Return) -30.95%
Risk-free rate: 4.5% (3-month US Treasury) • Based on 199 trading days
Sector Comparison (Consumer Defensive)
Compared to 29 peers in Consumer Defensive
Metric KVUE Sector Avg Percentile
P/E Ratio 23.27 13.47 57%
P/B Ratio 3.15 42.77 53%
ROE (%) 13.94% 74.68% 43%
Net Margin (%) 9.72% 8.72% 50%
Stock Score 507 500.0 57%
1Y Return (%) -16.54 % -3.26 % 27%
Percentile: 0% = worst in sector, 100% = best in sector
📊 Historical Price Analysis (Last 200 Days)

Loading chart...

Technical Analysis
Ticker Close SMA 5 SMA 8 SMA 13 SMA 50 SMA 200 RSI (14) MACD Volatility (%) Volume Signal SMA Decision
KVUE $17.69 $17.36 $17.31 $17.41 $17.96 $18.23 53.62 -0.16 17.81% 2964199 Building Long Mixed
Candlestick Patterns

There wasn't any recognizable pattern for the KVUE stock

News Sentiment
Ticker Headline Sentiment Source URL
KVUE This 5-Stock “Super Staples” Portfolio Yields Up To 11.3% Neutral forbes.com Read More
KVUE Kenvue to Announce First Quarter 2026 Results on May 7, 2026 Neutral businesswire.com Read More
KVUE Kimberly-Clark: This 5% Yielder Is A Buy Ahead Of The Kenvue Merger Neutral seekingalpha.com Read More
KVUE The Smartest Dividend Stocks to Buy With $2,000 Right Now Neutral fool.com Read More
KVUE Brokerages Set Kenvue Inc. (NYSE:KVUE) Target Price at $19.50 Neutral defenseworld.net Read More
Recent Insider Trading

No recent insider trading data available for KVUE

Company Information

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.

CEO Kirk L. Perry
Employees 22000
Country US
IPO Date 2023-05-04
Exchange NYSE
Website https://www.kenvue.com
Sector Consumer Defensive
Industry Household & Personal Products
Similar Stocks (Consumer Defensive - Household & Personal Products)
PG

The Procter & Gamble Company

Price: $148.59
Change: +1.98%
Market Cap: $3472B
P/E: 22.01
Score: E (492)
View Details
CL

Colgate-Palmolive Company

Price: $84.64
Change: +1.10%
Market Cap: $6790B
P/E: 32.18
Score: E (472)
View Details
KMB

Kimberly-Clark Corporation

Price: $96.75
Change: +0.16%
Market Cap: $3211B
P/E: 19.91
Score: E (482)
View Details
EL

The Estée Lauder Companies Inc.

Price: $77.31
Change: +1.18%
Market Cap: $2791B
P/E: -151.58
Score: E (342)
View Details
Rating Metrics Explained
DCF Score (Discounted Cash Flow)

Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.

ROE Score (Return on Equity)

Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.

ROA Score (Return on Assets)

Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.

D/E Score (Debt-to-Equity)

Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.

P/E Score (Price-to-Earnings)

Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.

P/B Score (Price-to-Book)

Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.

Rating Recommendations:

Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:

  • Strong Buy (5/5): Excellent score - strong positive indicator
    • The metric significantly outperforms industry averages (top 20% of companies)
    • Indicates exceptional financial health or attractive valuation in that category
  • Buy (4/5): Good score - positive indicator
    • Above-average performance (top 40% of companies)
    • Shows strong fundamentals with room for improvement
  • Neutral (3/5): Average score - neutral indicator
    • Performance in line with industry median (middle 20%)
    • Neither significantly positive nor negative signal
  • Sell (2/5): Below average - negative indicator
    • Below-average performance (bottom 40% of companies)
    • Suggests weakness in this particular metric
  • Strong Sell (1/5): Poor score - strong negative indicator
    • Significantly underperforms industry (bottom 20%)
    • Indicates potential risk or overvaluation in that category
Note: The overall rating combines all six component scores to provide a comprehensive investment assessment. No single metric should be used in isolation for investment decisions.